達剛控股(300103.SZ):眾德投資累計增持99.76萬股
格隆匯 12 月 18日丨達剛控股(300103.SZ)公佈,2020年12月18日,公司收到眾德投資送達的《關於增持公司股份進展情況的告知函》。
2020年9月2日至2020年12月18日期間,眾德投資通過深圳證券交易所證券交易系統以集中競價的方式累計增持公司股份99.76萬股,佔公司總股本的0.31%,增持的價格區間為11.50元/股-12.75元/股。
截至公告日,眾德投資共計持有公司股份99.76萬股,佔公司總股本的0.31%。
眾德投資將根據證券市場整體狀況並結合公司股票價格情況,繼續增持公司股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.